NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT02129322 2021-02-15
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Phase 2 Withdrawn
NCT02747537 2019-09-09
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
Phase 2 Withdrawn
NCT02908165 2018-01-10
Randomized Phase II Trial of Chemoembolization and Sorafenib
Yale University
Phase 2 Withdrawn
NCT02406508 2017-12-18
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
Delcath Systems Inc.
Phase 2 Withdrawn
NCT01851408 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00694291 2015-03-06
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT01736878 2013-05-17
SUMMIT
Eanm Research Ltd
Phase 2 Withdrawn
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn